Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: In human-powered vehicles, e.g., bicycles, etc., it is customary to use drum brakes, disc brakes or shoe brakes. Each of the braking systems has different advantages in terms of braking effect, system costs, ease of maintenance, etc. A brake unit with a modified structure for a vehicle is provided. For this purpose, a brake unit 14 for a vehicle 1 is disclosed, having a housing 15, having a brake body device 23, wherein the brake body device 23 supports a stationary brake partner of a brake apparatus 12 for the vehicle 1, wherein the housing 15 and/or the brake body device 23 defines a main axis H, having an actuator for moving the brake body device relative to the housing 15 in order to generate a braking force, wherein the stationary brake partner is formed as a brake disc 13.

Abstract: A brake device for a vehicle with at least one wheel, wherein the wheel defines a rotational axis, with a brake body device for the transmission of a brake force to the wheel, with a concentric brake cylinder for the generation of the brake force. The brake cylinder has an inner housing part for radial support on a wheel axle of the wheel and an outer housing part for axial support on the brake body device. The two housing parts can be moved relative to one another, and a pressure chamber which runs around the rotational axis is formed between the two housing parts. The brake device has an insulation device for the thermal insulation of the brake body device in the direction of the brake cylinder. The insulation device is arranged at least axially between the outer housing part and the brake body device.

Abstract: A drive module (1) for a small or mini vehicle (20), having a wheel axle (8), at least one wheel (2, 3), at least one motor device (4, 5) for producing and applying a drive torque to the at least one wheel (2, 3), and at least one braking device (6, 7) for braking the at least one wheel (2, 3). The drive module (1) further includes an evaluation and control device (12) for evaluating safety-relevant data (30) of the small or mini vehicle (20) and for controlling the drive module (1) on the basis of the evaluated safety-relevant data (30) and/or can be and/or is connected to the evaluation and control device.

Abstract: A wheel module for a vehicle is disclosed including a wheel, said wheel having a wheel rim; a wheel axle, the wheel rim being rotatably mounted on said wheel axle; and a braking device for braking the wheel, said braking device comprising a brake disc and a brake pad. The brake disc and the brake pad being mutually contactable in order to transmit a braking force F1 to the wheel rim, wherein the brake disc can be axially moved to contact the brake pad and the brake pad remains axially fixed.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: An electric axle drive unit for a motor vehicle, having an electric motor with a stator that is fixedly received in a housing, and a rotor that is rotatably mounted relative to the stator and rotationally coupled or coupleable to a wheel hub. A brake device is operatively connected to the wheel hub. The brake device has a first brake component fixedly supported on the housing, a second brake component rotationally fixed to the wheel hub that is frictionally connectable to the first brake component, and an actuation unit that applies a braking force that interconnects the brake components. One of the brake components has a brake disc element rotationally fixed to a support part and is displaceably received in the axial direction of a rotational axis of the wheel hub relative to the support part.

Abstract: An electric wheel drive unit (1) for driving a wheel of a motor vehicle is provided having a brake device (2) for braking the electric wheel drive unit (1) during operation, and a housing (3) which accommodates the brake device (2) in its interior (I). The brake device (2) is designed to convert kinetic energy into heat in order to perform braking, and to suck in a fluid in the axial direction (A) and to feed it in the radial direction (R) in order to cool the brake device (2) by a flow of fluid which is for the most part oriented radially and flows through the brake device (2).

Abstract: A wheel hub drive for a vehicle, having: a drive housing; a hub output mounted rotatably relative to the drive housing; a wheel brake for the hub output that has a stationary and a rotating braking partner, the stationary braking partner being connected to the drive housing for conjoint rotation therewith, and the rotating braking partner being connected to the hub output. The two braking partners are frictionally connected in a braking state, A parking brake for fixing the hub output relative to the drive housing. The stationary and rotating brake partners being movable relative to one another when the parking brake is actuated and being frictionally connected to one another in a parked state. The has a ramp mechanism for converting a rotary movement into a linear movement in order to transfer a parking force to the stationary and/or rotating brake partner.

Abstract: According to the invention, the control system consists of one or more global controllers configured to receive state data from the tower structures and tendons, via sensors and control an operating state of the wind generators correspondingly in a calculation method for avoiding load peaks and/or avoiding resonances. In a preferred embodiment, a local controller is configured to also process status data of the sensors from a near field of a building around the respective local controller.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: A dry double clutch for an electric axle includes a clutch unit and an actuation unit. The clutch unit has a first clutch device for connecting a drive shaft with a first output shaft, and a second clutch device, coaxial to the first clutch device, for connecting the drive shaft with a second output shaft. The actuation unit has a first actuation device for actuating the first clutch device, and a second actuation device for actuating the second clutch device. The first clutch device is closed when the first actuation device is not actuated, and the second clutch device is open when the second actuation device is not actuated. The first clutch device is arranged to be opened by a first pressure force from the first actuation device, and the second clutch device is arranged to be closed by a second pressure force from the second actuation device.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.